Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Field
-
develops new intellectual understanding Disseminate research findings for publication, research seminars, etc Supervise students on research related work and provide guidance to PhD students where
-
and beyond. Candidate Profile We welcome applicants with diverse backgrounds in experimental or computational biology who are excited by pioneering research directions. Qualifications PhD in molecular
-
projects that leverage our optical expertise to probe brain function Preferred Qualifications & Expertise: PhD in neuroscience, bioengineering, computational biology, or related field At least one strong
-
. You can read more about the project here . Who are you? You must hold a PhD degree in Natural Sciences or Engineering or at least have submitted your PhD thesis for assessment. Previous thematic
-
Supervise students on research-related work and provide guidance to PhD students where appropriate to the discipline Contribute to developing new computational models, techniques and methods Undertake
-
* Contribute to the supervision of PhD students and junior researchers Your Profile: * PhD in Bioinformatics, Computational Biology, Systems Biology, Biostatistics, or a related field – (Doctoral degree should
-
organoids will be plus. Dry lab: Highly motivated candidates with a PhD/MD degree in bioinformatics, genome science, systems biology, biomedical informatics, computational biology, machine learning, data
-
in English is provided. Application Requirements for Both Positions: All applicants must have obtained a PhD degree within the last 10 years. Please submit the following documents to the ICYS
-
Research Fellow (Fusion Shielding Materials) - School of Metallurgy and Materials - 105638 - Grade 7
a framework for the role. Person Specification or Required Knowledge, Skills, Qualifications, Experience Hold a PhD (or one near to completion) in a relevant area, such as Fusion Energy, Nuclear
-
oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor prognosis, and this clinic